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ABSTRACT 
This study demonstrates that logPoct-tol (difference between logPoctanol and logPtoluene) 
describes compounds propensity to form intramolecular hydrogen bonds (IMHB) and may be 
considered a privileged molecular descriptor for use in drug discovery and for prediction of IMHB 
in drug candidates. 
We identified experimental protocols for acquiring reliable logPoct-tol values on a set of compounds 
representing IMHB motifs most prevalent in Medicinal Chemistry, mainly molecules capable of 
forming 6-, 7-member IMHB rings. 
Furthermore, computational logPoct-tol values obtained with COSMO-RS software provided a good 
estimate of experimental results and can be used prospectively to assess IMHB. 
The proposed interpretation method based on logPoct-tol data allowed categorization of the 
compounds into 2 groups - with high propensity to form IMHB and poor propensity or poor 
relevance of IMHB.  
The relative 
1
H NMR chemical shift of an exchangeable proton was used to verify presence of 
IMHB and to validate the IMHB interpretation scheme.  
  
4 
 
1. INTRODUCTION 
The incorporation of an intramolecular hydrogen bond (IMHB) into a molecule is gaining a great 
deal of interest in drug design as indicated by the number of papers recently published in key 
Medicinal Chemistry journals. 
1-5
 The presence of IMHB has been shown to significantly alter 
molecular properties due to formation of various conformers that in turn influence solubility, 
permeability, PK/ PD processes, and protein binding affinity. 
6-9
 
The IMHB as described by Desiraju 
10
 is an attractive interaction in which an electropositive 
hydrogen atom intercedes between two electronegative fragments of the same molecule and holds 
them together. A hydrogen bond is strong enough to restrict rotation of fragments by forming most 
commonly 5-8 membered rings. Importantly, IMHBs are weak enough to allow these fragments to 
come apart and lose their orientational specificity in high dielectric media such as water. The 
chameleon like nature of an IMHB becomes apparent when one realizes that in water an IMHB is 
unlikely to form and the polar groups may serve to increase solubility by readily forming 
intermolecular hydrogen bonds with water.  Alternatively, molecules that can participate in IMHB 
shed water more readily when entering a low dielectric environment like a hydrophobic 
phospholipid bilayer.  In this circumstance IMHB results in lipophilic, less polar molecular 
conformations which are expected to have higher passive membrane permeability. 
11
 In other 
words, a decrease in polarity is sometimes achieved through the formation of IMHBs, where the 
hydrogen bond donor (HBD) and acceptor (HBA) atoms are effectively shielded from water, 
thereby reducing the energetic penalty of desolvation required in moving from an aqueous 
environment through a phospholipid bilayer. 
4
  
The consequences of IMHBs to medicinal chemists are significant but often under-recognized and 
seldom predicted. For instance, lipophilicity may be underestimated when determined by calculated 
logP (clogP) in molecules with IMHBs, while hydrogen bond donor and acceptor counts are 
overestimated. Additionally, clogP, as well as hydrogen bond donor and acceptor counts, are part of 
the ubiquitous Ro5 parameters 
12
 , used to predict drug like properties and permeability. When 
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IMHB are present these Ro5 counts can be effectively stretched, broadening drug like property 
space allowing more diverse drug design. 
9,13
  Likewise preferred property space for Central 
Nervous System (CNS) drugs may be extended when IMHB are present, as hydrogen bond donor 
count and clogP are both parameters in the CNS Multi-Parameter Optimization (CNS MPO) 
score.
14 
 In support of this notion it was also found that logPoct-alk correlates with brain penetration 
and oral absorption. 
15,16
  
 Recent systematic work incorporating IMHB considerations in drug design has been published by 
Kuhn and coworkers. 
17
  On the basis of pioneering work by Etter 
18
 and Bilton 
19
 and exhaustive 
searches of crystal structure databases, they derived propensities for IMHB formation of five- to 
eight-membered ring systems of relevance in drug discovery. The influence of IMHB on solubility, 
lipophilicity in octanol/water and permeability was also highlighted.  
Unfortunately, one cannot simply examine a given 2D structure and immediately delineate the 
presence of one or more IMHBs and determine their strength because the thermodynamic 
equilibrium of closed versus open conformations depend on a number of complex factors (e.g. 
geometry, type of solvent and others) 
20
 acting simultaneously. The most common tools used to 
investigate IMHBs are spectroscopy (NMR, infrared and Raman, microwave), diffraction (X-ray 
and neutron diffraction), calorimetry and theoretical methods.
21
 However, many of these techniques 
are not high throughput and data produced often require detailed interpretation by experts. These 
issues lead us to look for additional methods.   
LogP is one of the most widely used parameters in drug design and it has been considered for 
evaluation of IMHB 
8, 22, 23
. It has been demonstrated using solvatochromic equations that the 
difference between logP values obtained in different biphasic systems (logP), for example 
octanol/water and alkane/water (logPoct-alk = logPoct – logPalk), is informative of IMHB when the 
solvents are very different from each other. 
24
 More on differences in logP systems is given in 
Supporting Information (Annex S1, S3).   
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The idea that logPoct-alk is informative of IMHB and the reports that logPoct-alk correlates with 
brain penetration and oral absorbtion 
15, 16
 lead us to explore logPoct-tol (logPoct-tol = logPoct – 
logPtol. 
25-29
  
The investigation of IMHB by logP was proposed some time ago30, however this approach was 
not widely implemented mainly because the practical tools, both experimental and theoretical, to 
obtain logPalk data for large series of compounds were limited. 
The main goal of this study is to demonstrate that logPoct-tol (logPoct-tol = logPoct – logPtol ) 
distinguishes compounds with high propensity to form IMHB and to develop a protocol for its 
implementation in active Medicinal Chemistry projects where series of similar compounds are often 
available for relative comparisons.  
In order to achieve this goal we needed to address three subgoals. The first subgoal was to identify 
experimental methods that provide reliable logPoct-tol for large series of compounds. To accomplish 
this we used an ad hoc dataset of commercially obtained compounds representing many prevalent 
IMHB motifs and used miniaturized shake-flask and HPLC methods to acquire the individual 
logPoct and logPtol values.  
The second subgoal of the study was to validate logPoct-tol calculations where the molecular 3D 
structure is considered since it strongly influences the formation of IMHBs. We used the 
computational software COSMOtherm. The choice of COSMOtherm among a plethora of free and 
commercial computational tools available today for logP/logD  calculations
31
  was justified by two 
reasons: 1) unlike most logP calculators it uses the three dimensional structure of the molecules 
32-34
 
and 2) COSMOtherm  allows calculation of logP  values in non octanol/water systems. 
Furthermore, COSMOtherm is the only commercial a priori (not restricted by the availability of 
experimental data) method 
35
 available today.  
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The third subgoal of the study was to validate the IMHB interpretation scheme based on measured 
and calculated logPoct-tol data with an independent technique such as relative 
1
H NMR chemical 
shifts. 
 
2. RESULTS AND DISCUSSION 
2.1. DATASET SELECTION 
The set of 24 compounds and controls, shown in Figure 1, was created following the topologies 
identified by Kuhn et al. 
17
 in their systematic study of IMHB based on the analysis of the 
Cambridge Structures Database (CSD). It was observed in their study that 6- and 7- member IMHB 
ring systems are, by far, the most prevalent motifs in Medicinal Chemistry. In our study we used the 
numbered commercial compounds that contain several of the topologies described by Kuhn et al. 
and compared them with similar lettered compounds (controls) that are unable to form IMHB. We 
attempted to have simple test structures with one possible IMHB.  
In addition, the following aspects were taken into consideration while building the dataset to 
facilitate logP determination: solubility, ionization state, UV detection and commercial availability.  
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Figure 1. Chemical structures of investigated compounds; Kuhn’s topologies 17 and controls  
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2.2. LOGP DETERMINATION  
Table 1. Lipophilicity data (controls are colored in grey) 
 
octanol/water 
 
toluene/water 
  
octanol/water – 
toluene/water 
  
  
COSMO-RS 
logP SF_logP ElogD 
COSMO-RS 
logP SF_logP 
COSMO-RS 
logP SFlogP 
1 2.53 1.8 2.13 2.78 1.9 -0.25 -0.10 
2 4.0 **** 4.25 5.05 **** -1.05 N/A 
A 2.83 2.1* 2.68 2.44 1.6* 0.39 0.50 
4 4.50 **** 4.58 5.49 **** -0.99 N/A 
6 3.05 2.1* 2.97 3.81 2.1* -0.76 0.08 
B 3.17 1.91 2.58 3.76 1.96 -0.59 -0.05 
8 3.00 2.4* 3.20 3.69 1.9* -0.69 0.51 
9 2.71 *** 2.89 2.73 *** -0.02 *** 
C 2.41 N/A 2.92 1.43 N/A 0.98 N/A 
C2 0.59 0.46 1.1 -2.16 -2.46 2.75 2.92 
10 1.49 1.43 1.76 1.57 0.71 -0.08 0.72 
11 2.12 1.84 2.19 2.31 1.35 -0.19 0.49 
D 2.01 1.76 1.84 1.09 0.13 0.92 1.63 
12 -1.08 -0.56 -0.07 -2.73 -2.42 1.65 1.86 
E1 1.50 1.56 2.11 0.99 0.61 0.51 0.95 
13 2.40 0.15 ** -1.51 -1.63 3.91 1.78 
E2 2.38 1.76 ** 2.70 1.2 -0.32 0.56 
15 0.62 0.83 0.8 -0.15 -0.31 0.77 1.14 
16 2.47 2.17 3.1 2.73 1.64 -0.26 0.53 
F 0.78 0.95 1.3 -0.43 -1.01 1.21 1.96 
18 0.26 -0.17 0.13 -0.38 -1.75 0.64 1.58 
H 2.37 1.08 1.65 2.69 0.91 -0.32 0.17 
19 0.45 0.37 -0.69** -0.08 0.01 0.53 0.36 
I 2.41 0.97 -0.26** 1.43 1.06 0.98 -0.09 
*         uncertain value due to aggregation/quantification issues 
**       ionized at the pH of measurements 
***     unstable compound  
****   below quantification limits (too lipophilic) 
 
Experimental logP values (SF_logP in Table 1) were obtained in the presence of DMSO (up to 10% 
total volume) in the solution, which assisted solubility while also mimicking a widely accepted 
practice  of using DMSO stock solutions in high throughput assays in drug discovery programs, 
including logP/D measurements 
36-39
. As a result, experimental ΔlogPoct-tol data (SF_logP in Table 
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1) were obtained for most of the molecules in the dataset. More information about the influence of 
DMSO on logP is given in the Supporting Information (Annex S2). 
Theoretical lipophilicity values used in Table 1 were obtained with COSMOtherm and we refer to 
COSMO-RS logPoct and COSMO-RS logPtol as calculated values in octanol/water and toluene/water 
systems, respectively. Briefly, COSMOtherm software calculates logP from a chemical potential for 
any solvent system using the COSMO-RS method 
40
, which is based on a combination of the 
quantum chemical dielectric continuum solvation model (COSMO) with a statistical 
thermodynamic treatment of surface interactions. The method also allows prediction of the relative 
weight of each molecular conformation in the solvent using Boltzmann statistics. More details on 
the calculations are given in Section 4.4.2. 
Finally, the accuracy of each logP value is especially critical in this study if the logP to be used as 
a descriptor of IMHB. Therefore, whenever possible, we tried to verify logP values obtained by one 
method with another experimental or computed value. The results of the cross validation of 
lipophilicity data are summarized in Figure 2 and show an excellent agreement between data 
produced by different methods.  
The standard error of determination reported for SF_LogP 
41
 method is 0.1 (and thus 0.2 for logP). 
The Root Mean Square Errors (RMSE) derived from the regression analysis are listed on each plot. 
The RMSE for SF_logP vs. COSMO-RS logP for octanol (Fig. 2B) and toluene (Fig. 2C), are 0.5 
and 0.4, respectively, demonstrating again, similarity in COSMO-RS modeling across the two 
systems.  Apparently, the most significant bearing in this study is on the error in determination of 
ΔlogP values. The RMSE for SF_ΔlogP vs. COSMO-RS ΔlogP (Fig. 2D) is 0.29, which is slightly 
better than in each system separately, probably due to cancelling out of the DMSO effect. More 
details about the cross validation strategy 
42-44
 are given in the Supporting Information (Annex S2). 
 
Figure 2. Cross validation of lipophilicity data. A) Validation of experimental SF_logPoct with 
ElogD, B) Validation of computed COSMO-RS logPoct with experimental SF_logPoct, C) Validation 
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of experimental SF_logPtol with computed COSMO-RS logPtol and D) Validation of experimental 
SF_logP (error bars are shown) with computed COSMO-RS log,.  
 
 
2.3. logP ANALYSIS and an IMHB INTERPRETATION METHOD  
No general guidelines are reported in the literature on the interpretation of logP in relation to the 
presence and the strength of IMHBs. Therefore the analysis of logP data was aimed at obtaining 
an IMHB interpretation method. 
A B
C D
RMSE = 0.29 
RMSE = 0.50 
RMSE = 0.39 
RMSE = 0.29 
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As discussed earlier, it is assumed that toluene, similar to apolar solvents, promotes folded 
conformations and formation of IMHB when possible, whereas the reverse is true for molecules in 
water and, to a lesser degree, in octanol. Therefore, the difference between logPoct and logPtol (i.e. 
logP) should reflect the propensity of a compound to form IMHB. The logP value by itself does 
not indicate the formation of IMHB. However, trends are observed if comparisons made in a pair-
wise fashion for compounds in a series capable of forming IMHB (samples) and not capable of 
IMHB (controls). In particular, the comparative analysis of logPoct-tol in Table 1 reveals two 
possible situations: 
 logPoct-tol of the control is > (larger) than logPoct-tol of the sample  - Category I 
 logPoct-tol of the control is < (smaller) than logPoct-tol of the sample  - Category II 
The first situation (Category I), when logPoct-tol of control is larger than that for the sample, is 
found in the following matched groups: 1 and Control A; 8 and Control C2; 10, 11 and Control D; 
15, 16 and Control F. In these groups the sample prefers toluene to octanol when compared with the 
control, presumably because of significant amounts of folded conformers with a high propensity to 
form IMHB. 
The second situation (Category II), when the logPoct-tol of the control is lower than logPoct-tol of 
the sample, is found for the following groups: 6 and Control B;  12 and Control E1, for 13 and 
Control E2, for 18 and Control H and 19 and Control I. In these groups the sample prefers octanol 
to toluene, probably, due to a significant presence of extended conformers. This suggests that either 
the sample has a poor propensity to form IMHBs or the IMHB has a poor relevance to logPoct-tol. 
The influence of the experimental error associated with measured logPoct-tol value (+0.2 ; the error 
bars shown in Fig.2D) has to be considered in categorization of results. Apparently, in that 
“binning” categorization scheme, the consequence of the error is most significant for compounds 
with a small difference between logP of Sample and Control. Therefore, the classification 
threshold is defined by the error and the difference in logP has to be higher than 0.4, for clear 
13 
 
categorization. In other words, if logP values of Sample and Control are very close to each other 
the categorization becomes uncertain for that pair (example, 6 and Control B). However, 
substitution of the control with another molecule from the series could be recommended as a 
practical solution in a drug design project.  
Importantly, the calculated COSMO-RS ΔlogPoct-tol values presented in Table 1 demonstrate that the 
same pairs of compounds fall into the same categories as described above for experimental ΔlogPoct-
tol values. The only deviation was observed for compound 19 and Control I, which were placed into 
Category I by calculated ΔlogPoct-tol and into Category II by measured ΔlogPoct-tol. This discrepancy 
stems mostly from the significant difference between predicted and experimental logPoct value for 
the control I (2.41 and 0.97, respectively).  The COSMO-RS logPoct for control I is the most deviant 
predicted value in the set, as seen in Fig. 2B The deviant predicted value drives the error for 
COSMO-RS logPoct higher for the entire set. Recall, compound 6 and Control B categorization by 
experimental data are uncertain, as discussed above; however, COSMO-RS ΔlogPoct-tol calculated 
values assign this pair to Category I. 
This illustrates one benefit of using computed values where compounds lacking measured logP 
values can be categorized based on the calculated logP values. Here in particular, 4 and Control B; 
9 and Control C are placed into the Category I using calculated ΔlogPoct-tol values, even though the 
low solubility and instability of compounds 4 and 9, respectively, prevented us from obtaining 
measured ΔlogPoct-tol values. A second obvious benefit is the prospective use of calculated logP 
values in Medicinal Chemistry design on a series of virtual compounds.  
The IMHB interpretation scheme was further supported by a closer inspection of the properties of 
the molecular conformers generated using COSMOS-RS. The example of conformers for 
compounds 1 (Category I, high propensity to form IMHB) and 18 (Category II, low propensity to 
form IMHB) are visualized in Figure 3. The conformer 1_1 (top left in Figure 3) forms IMHB in 
any solvent (populated about 100% as evaluated in water, octanol and toluene) and contributes most 
14 
 
to the logP value.  The open conformers (as 1_2, top right in Figure 3) are poorly populated and 
largely more hydrophilic than the closed conformers. 
The three most populated conformers of 18 (18_1, 18_2, 18_3 in Figure 4) may or may not form 
IMHB. They show similar logPoct values and their difference in logPtol is less important than that 
found for compound 1.  
Figure 3. Examples of COSMO-RS results for conformations of compounds 1 (Category I, high 
propensity to form IMHB) and 18 (Category II, low propensity to form IMHB). The relative 
conformer populations in water (w), wet octanol (o) and toluene (t) are shown. For each conformer 
logPoct and logPtol were calculated ignoring all other conformations. 
 
These examples demonstrate that in contrast to 2D logP calculation methods, COSMO-RS gives a 
detailed view of conformational variability and supports that the presence of folded conformers 
15 
 
lowers logP value (1_1 and 18_3). As a consequence the comparison between logP of the sample 
and its control helps substantiate the propensity of the test molecules to form IMHB.  
This approach was applied to logP data available from the literature in cyclohexane/water 25 and  
1,2-dichloroethane/water systems 
29, 45
 and it revealed the same trends; data shown in Supporting 
Information (Annex S3).  
2.4. IMHB verification by NMR and crystallographic data 
To validate the IMHB interpretation scheme based on logP data, we set out to determine the 
relative 
1
H NMR chemical shift of an exchangeable proton at a single temperature. Generally, an 
exchangeable proton that is hydrogen bonded will be more deshielded (higher chemical shift value) 
than a similar exchangeable proton that is not hydrogen bonded. As a consequence, and in analogy 
with logP analysis, it requires a comparative analysis between two compounds (sample and 
control) within the same chemical series in order to evaluate the propensity to form IMHB using the 
NMR
 1
H chemical shift data of the exchangeable protons. 
Table 2. Correlation of COSMO-RS ΔlogP and NMR 1H Chemical Shift results and the percentage 
of crystallographic entries (%HB) with IMHB found by Kuhn and coworkers for the corresponding 
topologies 
17
 
 
CDCl3 
300K 
 CDCl3 sample- 
 CDCl3 control 
COSMO-RS 
ΔlogPcontrol-
ΔlogPsample 
%HB predicted 
by topology
17
 
 
Category 
1 8.69 2.63 0.64 93       I 
2 10.78 4.72 1.44 93                         I 
A 6.06 - - -  
4 12.12 8.44 0.4 90       I 
6 7.64 3.96 0.17 90       I 
B 3.68 - - -  
10 10.37 4.36 1 85       I 
11 10.44 4.43 1.11 85       I 
D 6.01 - - -  
12 6.1 0.58 -1.14 18      II 
E1 5.52 - - -  
15 9.24 4.66 0.44 81       I 
16 
 
16 11.76 7.18 1.47 81       I 
F 4.58 - - -  
18 3.9 0.6 -0.96 37      II 
H 3.3 - - -  
 
The presence of IMHB in the studied compounds is indicated by the chemical shift of the 
exchangeable proton involved in IMHB, which moves upfield in comparison with the control 
compound that cannot form IMHB. In particular, this upfield shift is clearly marked for all 
compounds that were amenable to measurements in CDCl3 (Table 2) and DMSO (Supporting 
Information Table S2). Compounds 12 and 18 do not follow this trend and have only minor 
chemical shift differences. This further supports that 12 and 18 are correctly binned in Category II 
indicating that these compounds are unlikely to form IMHB to a significant extent. More details 
about NMR strategy 
46
 can be found in the Supporting Information (Annex S4).  
In order to examine logP and NMR data for trends, the differentials between logP and  CDCl3 
values for “samples” and “controls” are calculated (Table 2) and graphically presented in Fig.4, A 
and B, respectively.  
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Figure 4. COSMO-RS ΔlogP vs. NMR chemical shift trends demonstrated on differentials between 
values for sample and control. A) COSMO-RS (ΔlogPcontrol - ΔlogPsample); B) δ CDCl3 sample –
 δ CDCl3 control. 
 
Figure 4 shows that the logP differentials (control-sample) for series of compounds 1, 2, A; 4, 6, 
B; 10, 11, D; 15, 16, F are positive. The differential for the  CDCl3 values for these samples is 
between 2 and 8. These compound pairs are from Category I, where samples have high propensity 
to form IMHB as described earlier. 
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The logP differentials for compounds 12, E1 and 18, H are negative. And the differential of the  
CDCl3 values for these samples is relatively low, below 0.6. These pairs are from Category II, 
characterized by poor propensity to form IMHB. 
Therefore, both differentials - COSMO-RS (logPcontrol- logPsample) and ( CDCl3 sample-  
CDCl3 control) - separated compounds into the same two groups, Category I and Category II, 
respectively.  
Furthermore, the frequency of hydrogen bond occurrences associated with each topology, %HB, as 
defined by Kunh and coworkers 
17,
 is much higher for molecules we identified as having higher 
propensity to IMHB (Category I), than for structures with poor propensity to IMHB (Category II ).  
The crystallographic structures of compounds 9 and 12 were retrieved from the CSD (accessed on 
May 6, 2013) with codes XENKAD and FULSUA, respectively. Both compounds showed presence 
of IMHB in the solid state according to Kuhn’s criteria. The %HB for topologies represented by 9 
and 12 are 93.5% and 18%, respectively. This suggests that 9 (Figure 1) has high propensity to form 
IMHB not only in the solid state, but also in solution. The reverse is true for 12 which is expected to 
have poor propensity to form IMHB in solution. In our studies, no experimental logP data could 
be determined for 9, while calculated logP values are in line with category I compounds (high 
propensity to form IMHB). The experimental logP and NMR data for 12 enabled its classification 
in category II (low propensity to form IMHB). These findings demonstrate differences in the 
formation of IMHB in solid state and liquid environments. 
The nature of the division into Category I and II should be studied further for the purpose of 
identifying structures with high propensity to IMHB. 
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3. CONCLUSIONS 
In this work ΔlogPoct-tol was used to evaluate the propensity of compounds to form IMHB. In 
particular we propose an IMHB interpretation scheme that enables categorization of compounds in 
two categories 
 logPoct-tol of the control is > (larger) than logPoct-tol of the sample    - Category I 
 logPoct-tol of the control is < (smaller) than logPoct-tol of the sample  - Category II 
where compounds with high propensity to IMHB fall into Category I and compounds with poor 
propensity to IMHB fall into Category II. 
This approach could be applied in early discovery projects using fast shake flask logPoct-tol 
measurements from DMSO solutions using small quantities of compound. Furthermore, we suggest 
that calculated values can be used prospectively on virtual compounds within a series to evaluate 
IMHB and potentially stretch the druggability mnemonics Ro5 and CNS MPO score to include 
more diverse structures. 
Furthermore, it was observed that: 
1. Determination of the IMHB presence requires analysis of data obtained in the same matrix 
environment on structures capable and not capable of IMHB. 
2. logPoct-tol calculations by COSMOtherm provided good estimation of logP values and 
could be applied for the IMHB interpretation on virtual compounds, including “ideal” 
virtual controls, as they need not be made or tested experimentally. That approach is 
especially attractive in case of prospective design of IMHB and on compounds not lending 
themselves to experimental studies by NMR or logP due to solubility or other issues. 
3. The frequency of hydrogen bond occurrences associated with each topology, %hb, as 
defined by Kuhn and coworkers 
17
 is much higher for molecules we identified as having 
higher propensity to IMHB (Category I), than for structures with poor propensity to IMHB 
(Category II ). 
20 
 
According to the results reported here, logPoct-tol should be included in Medicinal Chemistry 
design for optimization of physical chemical properties, as a privileged molecular descriptor for 
delineating the propensity of compounds to form IMHB.  
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4. EXPERIMENTAL SECTION 
4.1. MATERIALS  
All compounds were obtained commercially from Sigma-Aldrich (#,1,2,8,9,10,11,15,16, 18,C,D,F), 
Alfa Aesar (#12, 13, E1, E2), Asinex (#4), SAFC/Japan (#6), ChemBridge (A), ChemDiv (B), ACE 
Synthesis (H), Life Chemicals (#19, I) and used as received. The purity of compounds was >95%, 
as specified in accompanying documentation, The degradation observed on compound #9 lead to 
exclusion of all experimental measurements on that compound.  
4.2. LOGP MEASUREMENTS 
4.2.1. Miniaturized shake-flask. An automated, miniaturized shake flask method in a 96-well 
format using the automated liquid handling capabilities of the Analiza Automated Discover 
Workstation (ADW) and ANTEK chemilimunescent Detector was used. 
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Sample Preparation: The compounds were prepared at 3 concentrations spanning one order of 
magnitude in Universal Buffer (composed of 0.15 M NaCl and 0.1 M each of phosphoric, boric, 
and acetic acids, adjusted to the appropriate pH with NaOH). The pH was chosen based on the pKa 
of the compounds to have them as neutral species for the determination of logP values.  
 ΔlogPoct-tol obtained from dry powder dissolved in Universal Buffer. The resulting samples 
were added as 250µL aliquots into 250µL of organic phase (saturated with the 
corresponding buffer), in triplicate.  
 ΔlogPoct-tol obtained from samples dissolved in DMSO. DMSO stock solutions (30, 15 and 
3mM) were prepared. Samples (50µL) were added to systems containing 200µL buffer 
phase and 250µL organic phases, in triplicate. 
LogP measurements were done at pH=7.4 on most compounds. A few compounds were measured 
at other pHs where they were in neutral form. For example, 1, 2, 4 and A were considered to be 
fully neutral over pH range 1 to 9. At the same time, 6 and B are fully neutral in pH range above 6-
7 and so are 15, 16 and F.  Neutrality was not fully verified for 8, 13 (two acidic moieties) and E2 
22 
 
(acidic pKa about 2.8) and 19 and I (basic pKa about 9-10). pKa and pH values listed in the 
Supplemental Information.  
Partitioning and Quantitation  
The plates were sealed, vortexed, and centrifuged to aid in phase settling. 
The equimolar nitrogen response of the chemiluminescent nitrogen detector was calibrated using 
standards which span the dynamic range of the instrument, from 0.08 to 4500µg/mL nitrogen. The 
ADW is used to withdraw aliquots from both the top and bottom phases in each system. These 
aliquots were quantified using the calibration curve and the logarithm of the ratio of the 
concentration in the top phase to the concentration in the bottom phase is calculated as logP.  
 Quantification limits in compound detection in one of the phases, which is general limitation of 
shake-flask method for logP values above 3.0 or below -3.0, were found.  In our set the 
concentration of compounds 6, 8 and control A in the aqueous phase was near or below the 
quantification limit in both octanol/water and toluene/water systems, and therefore, an accurate 
logPoct or logPtol could not be determined for these compounds. 
4.2.2. ElogD An automated RP-HPLC method developed earlier in our laboratories was used for 
logD_pH7.4 measurements. 
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 The retention of each compound is obtained at 3 different 
concentrations of methanol in the mobile phase and extrapolated to 0% methanol (100%water). The 
column is Supelcosil LC-ABZ, 5 um, 4.6 x50 mm. The Mobile Phase is comprised of 15-75% of A 
and 85-25% of B, consequently, where A is methanol with addition of 0.25% 1-octanol. The Mobile 
Phase B consists of 20 mM of MOPS (morpholine-propane-sulfonic acid) buffer prepared in 
octanol saturated water. Samples were prepared in 1/1 Methanol/water at about 100 ug/ml. UV 
detection at 5 wavelength – 210, 225, 245, 275 and 310 was used. 
4.3. NMR  
Samples were prepared at 250uM, 150uM or 100uM directly in NMR solvent and 
1
H spectra were 
collected every 5 K over a 35K range. Temperature range of 280 K to 315K was used for CDCl3 
and a temperature range of 300K to 335K was used for DMSO-d6. Spectra were collected on a 
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Bruker 600MHz equipped with a 5mm inverse TCI cryoprobe or a Bruker 500MHz spectrometer  
with a 5mm SmartProbe; both with a BVT3200  temperature control unit and BCU-05 cooling unit. 
Temperature was equilibrated within 0.1K for 10-15 minutes prior to each experiment. The solvent 
peak was used as reference. CDCl3 was treated with base immediately prior to analysis to remove 
residual acid. 
4.4. IN-SILICO TOOLS 
4.4.1. COSMO-RS calculations Diverse sets of conformations were generated using mixed 
MCMM/Low-Mode algorithm and OPLS_2005 forcefield as implemented in MacroModel program 
(MacroModel; Schrodinger, LLC, New York, NY. 2011. http://www.schrodinger.com). The 
generated conformations were further optimized in aqueous media by the Turbomole package 
(TURBOMOLE, TURBOMOLE V6.3 2011, a development of University of Karlsruhe and 
Forschungszentrum Karlsruhe GmbH, 1989-2007, TURBOMOLE GmbH, since 2007; available 
from http://www.turbomole.com)  using the BP86 density functional 
47-49
 with a TZVP 
50
 basis set  
(BP-TZVP-COSMO level of theory). The generated screening charge densities of all conformations 
were used for COSMOtherm (Eckert F, Klamt A. 2012. COSMOtherm, Version C3.0 Release 
12.01) calculations of logPoct, logPtol and logPoct-tol properties.  
4.4.2. pKa calculations. pKa calculations were performed using MoKa (Molecular Discoveries, 
Ltd, v.1.1.0 ) and ACDlabs v. 12.1.  
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